Joseph Kupferman
Global Clinical Head AstraZeneca
Seminars
Tuesday 17th March 2026
Panel Discussion: Advancing Drug Development in Cardiovascular-Kidney-Metabolic (CKM) Syndrome
8:00 am
- Explore our evolving understanding of the pathophysiology linking cardiovascular, kidney and metabolic disorders
- Identify when and how overlapping CKM phenotypes can be leveraged to design more efficient clinical trials
- Discuss next steps in integrated drug development and regulatory frameworks for CKM components with shared mechanistic drivers
Wednesday 18th March 2026
Development of Balcinrenone/Dapagliflozin Combination in Chronic Kidney Disease
11:00 am
- Pre-clinical efficacy of balcinrenone, a novel MRA with a differentiated mode of action
- In phase 2 trials, balcinrenone/dapagliflozin was safe and reduced albuminuria in patients with CKD, with minor impacts on serum potassium levels
- Phase 3 development in heart failure and CKD
